Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) on Tuesday, soared 2.17% from the previous trading day, before settling in for the closing price of $7.38. Within the past 52 weeks, BCRX’s price has moved between $4.03 and $9.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 169.91% over the last five years. The company achieved an average annual earnings per share of 83.02%. With a float of $197.13 million, this company’s outstanding shares have now reached $208.54 million.
The firm has a total of 580 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.19%, operating margin of -0.54%, and the pretax margin is -19.29%.
Biocryst Pharmaceuticals Inc (BCRX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Biocryst Pharmaceuticals Inc is 5.66%, while institutional ownership is 78.45%. The most recent insider transaction that took place on Dec 13 ’24, was worth 52,780. In this transaction Director of this company sold 7,000 shares at a rate of $7.54, taking the stock ownership to the 86,638 shares. Before that another transaction happened on Dec 13 ’24, when Company’s Director proposed sale 7,000 for $7.51, making the entire transaction worth $52,584.
Biocryst Pharmaceuticals Inc (BCRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 83.02% per share during the next fiscal year.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Trading Performance Indicators
Biocryst Pharmaceuticals Inc (BCRX) is currently performing well based on its current performance indicators. A quick ratio of 2.58 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach 0.23 in one year’s time.
Technical Analysis of Biocryst Pharmaceuticals Inc (BCRX)
Analysing the last 5-days average volume posted by the [Biocryst Pharmaceuticals Inc, BCRX], we can find that recorded value of 4.51 million was better than the volume posted last year of 3.36 million. As of the previous 9 days, the stock’s Stochastic %D was 12.76%. Additionally, its Average True Range was 0.43.
During the past 100 days, Biocryst Pharmaceuticals Inc’s (BCRX) raw stochastic average was set at 26.18%, which indicates a significant increase from 14.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.41% in the past 14 days, which was lower than the 54.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.11, while its 200-day Moving Average is $7.56. Now, the first resistance to watch is $7.74. This is followed by the second major resistance level at $7.94. The third major resistance level sits at $8.21. If the price goes on to break the first support level at $7.27, it is likely to go to the next support level at $7.00. Now, if the price goes above the second support level, the third support stands at $6.80.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Key Stats
Market capitalization of the company is 1.58 billion based on 208,960K outstanding shares. Right now, sales total 450,710 K and income totals -88,880 K. The company made 131,530 K in profit during its latest quarter, and -26,800 K in sales during its previous quarter.
